

Linköping University Post Print

Molecular identification of ^{bla}CTX-M and ^{bla}OXY/K1 beta-lactamase genes in *Enterobacteriaceae* by sequencing of universal M13-sequence tagged PCR-amplicons.

Hans-Jurg Monstein, Maria Tärnberg and Lennart Nilsson

N.B.: When citing this work, cite the original article.

Original Publication:

Hans-Jurg Monstein, Maria Tärnberg and Lennart Nilsson, Molecular identification of ^{bla}CTX-M and ^{bla}OXY/K1 beta-lactamase genes in *Enterobacteriaceae* by sequencing of universal M13-sequence tagged PCR-amplicons., 2009, BMC infectious diseases, (9), 1, 7.

<http://dx.doi.org/10.1186/1471-2334-9-7>

Copyright: BioMed Central

<http://www.biomedcentral.com/>

Postprint available at: Linköping University Electronic Press

<http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-17021>

Molecular identification of *bla*CTX-M and *bla*OXY/K1 β -lactamase genes in *Enterobacteriaceae* by sequencing of universal M13-sequence tagged PCR-amplicons

Hans-Jürg Monstein,^{1,2*} Maria Tärnberg,² and Lennart E. Nilsson²

¹Clinical Microbiology-LMC, University Hospital S-581 85 Linköping, Sweden

²Department of Clinical and Experimental Medicine,² Faculty of Health Sciences, Linköping University, S-581 85 Linköping, Sweden;

Email:

*Hans-Jürg Monstein: hans-jurg.monstein@liu.se

Maria Tärnberg, maria.tarnberg@liu.se

Lennart E. Nilsson, lennart.e.nilsson@liu.se

*Corresponding author:

Abstract

Background: Plasmid encoded *bla*CTX-M enzymes represent an important sub-group of class A β -lactamases causing the ESBL phenotype which is increasingly found in *Enterobacteriaceae* including *Klebsiella* spp. Molecular typing of clinical ESBL-isolates has become more and more important for prevention of the dissemination of ESBL-producers among nosocomial environment.

Methods: Multiple displacement amplified DNA derived from 20 *K. pneumoniae* and 34 *K. oxytoca* clinical isolates with an ESBL-phenotype was used in a universal CTX-M PCR amplification assay. Identification and differentiation of *bla*CTX-M and *bla*OXY/K1 sequences was obtained by DNA sequencing of M13-sequence-tagged CTX-M PCR-amplicons using a M13-specific sequencing primer.

Results: Nine out of 20 *K. pneumoniae* clinical isolates had a *bla*CTX-M genotype. Interestingly, we found that the universal degenerated primers also amplified the chromosomally located K1-gene in all 34 *K. oxytoca* clinical isolates. Molecular identification and differentiation between *bla*CTX-M and *bla*OXY/K1-genes could only be achieved by sequencing of the PCR-amplicons. *In silico* analysis revealed that the universal degenerated CTX-M primer-pair used here might also amplify the chromosomally located *bla*OXY and K1-genes in *Klebsiella* spp. and K1-like genes in other *Enterobacteriaceae*.

Conclusion: The PCR-based molecular typing method described here enables a rapid and reliable molecular identification of *bla*CTX-M, and *bla*OXY/K1-genes. The principles used in this study could also be applied to any situation in which antimicrobial resistance genes would need to be sequenced.

Background

Plasmid encoded *bla*CTX-M enzymes represent an important sub-group of class-A β -lactamases which hydrolyse broad-spectrum β -lactam antibiotics causing an extended spectrum β -lactamase (ESBL) phenotype, which is increasingly found in enterobacterial species including *Klebsiella* [1, 2]. To date, over 60 different CTX-M-type β -lactamases have been described [3] and divided into five different clusters that reflect similarity at the amino-acid sequence level, namely *bla*CTX-M-1, *bla*CTX-M-2, *bla*CTX-M-8, *bla*CTX-M-9, *bla*CTX-M-25 [2], respectively. More recently, it has been suggested that *bla*CTX-M-45 forms a new, separate cluster [4].

Due to constitutive expression of a chromosomal class A β -lactamases [5], *Klebsiella oxytoca* was shown to have a high level resistance to ceftriaxone and cefotaxime [6]. Originally, this class A β -lactamase was named K1 [7] and later on referred to as KOXY [8] or *bla*OXY [6]. Sequence diversity of the chromosomally located *K. oxytoca* K1-gene and the existence of discrete groups of *bla*OXY-1 and *bla*OXY-2 genes has been described in detail [5, 9].

Numerous PCR-based typing assays for the identification of *bla*CTX-M genes have been developed. Initially, detection of all members belonging to specific *bla*CTX-M groups was achieved by combining multiple PCR amplification assays [10, 11]. To avoid multiple CTX-M PCR amplification steps, Boyd and co-workers [12] designed a pair of universal, degenerated CTX-M primers, allowing the amplification of hitherto all known *bla*CTX-M genes. However, identification of a *bla*CTX-M genotype at the nucleotide level often required cloning of the PCR-amplicons, followed by DNA sequencing. These methods are labour intensive, time-consuming, expensive and moreover, require a battery of amplicon specific sequencing primers.

In this study, we report on the use of a simple, accurate and universal CTX-M PCR amplification and sequencing assay well suited for high-throughput analysis.

Methods

Screening of *Klebsiella* spp. for cephalosporin resistance during 2001-spring 2007

At the Department of Clinical Microbiology, University Hospital Linköping, susceptibility testing was performed on all *Klebsiella pneumoniae* and *K. oxytoca* clinical isolates. Cefadroxil was used for the screening of cephalosporin resistance which was followed up by testing of resistant isolates with cefotaxime and ceftazidime or direct testing with cefotaxime and ceftazidime [14]. A biochemical panel for identification and differentiation of *Klebsiella* spp. was used. Indole-negative *Klebsiella* spp. clinical isolates were identified as *K. pneumoniae* and indole-positive clinical isolates as *K. oxytoca*.

Phenotypic ESBL-screening

All cefotaxime and/or ceftazidime resistant clinical isolates were phenotypically screened by Etest using ceftazidime and cefotaxime with and without clavulanic acid (bioMerieux Sverige AB, Askim, Sweden). A reduction of MIC by ≥ 3 twofold dilutions of the cephalosporin in the presence of clavulanic acid, i. e. a MIC ratio of ≥ 8 or the presence of phantom- or deformation zones was considered indicative of an ESBL-phenotype. Clinical isolates were stored in glycerol containing Nutrient-broth No 2 (Lab M, Bury, UK) at -70°C until analysis.

Susceptibility testing of *K. oxytoca* with K1-genes and *K. pneumoniae* with ^{bla}CTX-M genes

MIC-values for cefotaxime, ceftazidime and piperacillin/tazobactam were determined with Etest (bioMerieux Sverige AB, Askim, Sweden).

Bacterial type and reference strains

Control strain *K. oxytoca* 1980K1 was kindly provided by Dr. D. Livermore, Health Protection Agency, Antibiotic Resistance Monitoring and Reference Laboratory, London, UK. Type strains were purchased from the American Type Culture Collection [15] or the Culture Collection University of Gothenburg [16]; *K. pneumoniae* ATCC 700603, *K. pneumoniae* CCUG 54718, and *K. oxytoca* CCUG 15717^T.

Multiple displacement amplification of bacterial DNA

To perform multiple genotyping analysis of our growing collection of CTX-M suspected *K. pneumoniae* and *K. oxytoca* of clinical origin and omitting tedious bacterial culturing, sufficient amounts of bacterial DNA were produced by means of multiple displacement amplification of bacterial DNA [17]. For that purpose, bacteria from frozen cultures (1 µl) and from the reference strains were added to a GenomiPhi-DNA V2 amplification-kit cocktail as recommended by the manufacturer (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).

Universal ^{bla}CTX-M gene PCR amplification

A PCR amplification assay was carried out using 10 pmol of each universal degenerated primer *M13-CTX-M.U1.SE* (CGTTGTAAAACGACGGCCAGTGAATGTGCAGYACCAGT AARGTKATGGC) and *CTX-M.U2.AS* (TGGGTRAARTARGTSACCAGAAYCAGCGG) targeting the CTX-M and OXY/K1-enzyme genes [modified from 12] and a HotStarTaq-Master mix (Qiagen GmbH, Hilden, Germany) in a final reaction volume of 25 µl using an Applied Biosystems thermo cycler 2720 (Applied Biosystems, Foster City, USA) and 200 µl thin-walled reaction tubes. This yields an approximately 600 bp PCR amplicon corresponding to 68 % of the CTX-M and OXY/K1-enzyme encoding nucleotide sequences.

PCR amplification conditions were as follows: initial denaturation step at 95° C for 15 min; 30 cycles of denaturation at 95° C for 30 s; annealing at 55° C for 30 s; extension at 72° C for 2 min, and a final extension step at 72° C for 10 min. Subsequently, PCR-amplicons were separated electrophoretically on a precast 2% agarose E-gel (Invitrogen, Carlsbad, CA, USA).

DNA sequence analysis

DNA sequence analysis of M13-sequence tagged CTX-M PCR-amplicons was carried out using a M13 uni (-21) primer by a customer DNA sequencing service (Eurofins MWG Operon GmbH, Martinsried, Germany). Prior to DNA sequencing, PCR-amplicons were treated with ExoSAP-IT to inactivate excess of oligonucleotide primers, following the supplier's protocol (USB Europe GmbH, Staufien, Germany). The PCR products were then lyophilised and sequenced. Generated DNA sequences were aligned, edited and compared with *bla*CTX-M DNA and *bla*CTX-M-like DNA sequences using the CLC bioinformatics freeware v.3.2.3 [18]. *bla*CTX-M, *bla*OXY, K1, and K1-like DNA sequences were retrieved from the NCBI Entrez Nucleotide database [19].

***In silico* DNA sequence analysis**

*bla*CTX-M type strains *E. coli bla*CTX-M-1 [GenBank:X92506] (*bla*CTX-M Group 1), *E. coli bla*CTX-M-9 [GenBank:AF189721] (*bla*CTX-M Group 9), *E. coli bla*CTX-M-15 [GenBank:AY044436] (*bla*CTX-M Group 1), *E. coli bla*CTX-M-25 [GenBank:AF518567] (*bla*CTX-M Group 25), *E. coli bla*CTX-M-28 [GenBank:AJ549244] (*bla*CTX-M Group 25), *Salmonella Typhimurium bla*CTX-M-2 [GenBank:X925079] (*bla*CTX-M Group 2), *Citrobacter freundii bla*CTX-M-3 [GenBank:Y10278] (*bla*CTX-M-Group 1), *Citrobacter amalonaticus bla*CTX-M-8 [GenBank:AF189721] (*bla*CTX-M Group 8), *K. oxytoca* K1-genes [GenBank:AY077482–AY077489, AF473577, AY055205], *K. oxytoca bla*OXY-1

[GenBank:Y17715], *bla*OXY-2 [GenBank:Y17714], *bla*OXY-3 [GenBank:AF491278], *bla*OXY-4 [GenBank:AY077481], *bla*OXY-5 [GenBank:AJ871872] and *bla*OXY-6 [GenBank:AJ871879], *K. oxytoca* *bla*CTX-M-3 [GenBank:AB185840] (*bla*CTX-M Group 1) and *bla*CTX-M-35 [GenBank:AB176534] (*bla*CTX-M Group 1), chromosomally encoded β -lactamase genes from *Citrobacter sedlakii* Sed-1 [GenBank:AF321608], *Citrobacter amalonaticus* CdiA [GenBank:X62610], *Citrobacter koseri* CKO [GenBank:AF477396], *Proteus vulgaris* K1 [GenBank:D29982], *Proteus vulgaris* CumA [GenBank:X80128], *Proteus penneri* HugA [GenBank:AF324468] and the universal degenerated primers CTX-M.U1.SE and CTX-M.U2.AS, respectively (Fig. 1), were aligned using ClustalW [20]. A dendrogram consisting of all partial DNA sequences used for primer comparison in figure 1 and DNA sequences derived from the clinical isolates was constructed using the CLC bioinformatics freeware v.3.2.3 [18] and UPGMA clustering (Fig. 2). DNA sequences were edited to comprise the relevant DNA sequences between the two universal degenerated CTX-M primers (Fig. 1).

Results

Distribution of *Klebsiella* spp.

The number of *K. pneumoniae* and *K. oxytoca* clinical isolates of each year was in the range 457 to 864 (*K. pneumoniae*) and 270 to 455 (*K. oxytoca*), respectively, comprising 99% of the genus *Klebsiella* collected and analysed at the Department of Clinical Microbiology, University Hospital, Linköping, Sweden.

Screening of cephalosporin resistance and ESBL-phenotype

The cefadroxil resistance rate was in the range of 1.5% to 3.2% for *K. pneumoniae* and 3.7% to 6.4% for *K. oxytoca*. Twenty *K. pneumoniae* and 34 *K. oxytoca* clinical isolates were

Figure 1: Partial DNA sequence alignment of (A) CTX-M type sequences *E. coli* CTX-M 1 (Group 1), *E. coli* CTX-M-9 (Group 9), *E. coli* CTX-M-15 (Group 1), *E. coli* CTX-M-25 (Group 25), *E. coli* CTX-M-28 (Group 2), *S. typhimurium* CTX-M-2 (Group 2), *C. freundii* CTX-M-3 (Group 1), *C. amalonaticus* CTX-M-8 (Group 8); (B), *K. oxytoca* CTX-M-3 (Group 1) and *K. oxytoca* CTX-M-35 (Group 2), (C) chromosomally CTX-M-like sequences *K. oxytoca* K1, *K. oxytoca* OXY-1 to OXY-6, *C. sedlakii* Sed-1, *C. amalonaticus* CdiA, *C. koseri* CKO, *P. vulgaris* K1, *K. vulgaris* CumA, and *P. penneri* HugA genes and the universal degenerated CTX-M-U1.SE and CTX-M-U2. AS primers. Dashes indicate sequence homologies. The degenerated nucleotide sequence positions in the primers and its corresponding nucleotides in the aligned genes are indicated in grey. For clarity, sense and antisense DNA sequences of the universal degenerated CTX-M-U2.AS (reverse) primer are given.

CTX-M universal primer				CTX-M-U1.SE		CTX-M-U2.AS	
3' to 5'direction (reverse)				5' --ATGTGCAGYACCAGTAAAGTKATGGC--3'		3' --GGCGACYAAGACCASTGRATRAARTGGGT--5'	
5' to 3'direction (forward)						5' --CCGCTGRTTCTGGTSACYTAYTTYACCCA--3'	
A			nucleotide Position				nucleotide position
<i>E. coli</i>	CTX-M-1	X92506	273	5' --ATGTGCAGCACCAGTAAAGTKATGGC--3'		5' --CCGCTGATTCTGGTCACTTACTTCACCCA--3'	865
<i>S. typhimurium</i>	CTX-M-2	X92507	216	-----T-----G-----		-----G-----C-----T-----	808
<i>C. freundii</i>	CTX-M-3	Y10278	211	-----T-----G-----		-----T-----G-----C-----T-----	803
<i>C. amalonaticus</i>	CTX-M-8	AF189721	484	-----T-----G-----		-----T-----G-----C-----T-----	1076
<i>E. coli</i>	CTX-M-9	AF174129	6546	-----T-----T-----		-----G-----G-----C-----T-----T-----	7138
<i>E. coli</i>	CTX-M-15	AY044436	1646	-----T-----G-----		-----G-----G-----C-----T-----	2238
<i>E. coli</i>	CTX-M-25	AF518567	2531	-----T-----G-----		-----CG-----G-----	3123
<i>E. coli</i>	CTX-M-28	AJ549244	211	-----T-----G-----		-----G-----G-----C-----T-----	803
B							
<i>K. oxytoca</i>	CTX-M-3	AB185840	211	-----T-----G-----		-----G-----G-----C-----T-----	803
	CTX-M-35	AB176534	211	-----T-----G-----		-----G-----G-----C-----T-----	803
C							
<i>K. oxytoca</i>	K1	AY077482	372	-----G-----G-----		-----G-G-----G-C-T-T-----	964
		AY077483	390	-----G-----G-----		-----G-G-----G-C-T-T-----	982
		AY077484	389	-----G-----G-----		-----G-G-----G-C-T-T-----	981
		AY077486	391	-----G-----G-----		-----G-G-----G-C-T-T-----	983
		AY077485	391	-----G-----G-----		-----G-AT-A-----C-T-T-----	983
		AY077487	384	-----G-----G-----		-----G-AT-A-----C-T-T-----	976
		AY077488	366	-----G-----G-----		-----G-AT-A-----C-T-T-----	958
		AY077489	356	-----G-----G-----		-----G-AT-A-----C-T-T-----	948
		AF473577	391	-----G-----G-----		-----AT-A-----C-T-T-----	983
		AY055205	389	-----G-----G-----		-----G-AT-A-----C-T-T-----	981
<i>K. oxytoca</i>	Oxy-1	Y17715	357	-----G-----G-----		-----G-G-C-----G-C-T-T-----	949
	Oxy-2	Y17714	351	-----G-----G-----		-----G-AT-A-----C-T-T-----	943
	Oxy-3	AF491278	385	-----T-----G-----		-----G-AT-A-----T-T-----	977
	Oxy-4	AY077481	393	-----G-----G-----		-----G-G-A-----G-C-T-T-----	985
	Oxy-5	AJ871872	208	-----G-----G-----		-----G-G-----G-C-T-T-----	800
	Oxy-6	AJ871879	211	-----G-----G-----		-----G-GT-A-----G-C-T-T-----	803
<i>C. sedlakii</i>	Sed-1	AF321608	223	-----G-----G-C-A-----		-----G-G-----A-C-T-T-A-----	815
<i>C. amalonaticus</i>	CdiA	X62610	385	-----T-----GAC-----T		-----C-C-----C-T-A-----	977
<i>C. koseri</i>	CKO-1	AF477396	264	-C-C-A-TGA--G-G-C-C-----		--TT-C-CG--T-TC-TA-T-A-----	818
<i>P. vulgaris</i>	K1	D29982	428	---GCA--T--A--G--T-----		--AT-A--T-A--GT--T--A-----	1020
<i>P. vulgaris</i>	CumA	X80128	1475	---GCA--T--A--G--T-----		--AT-A--T-A--GGTC--T--A-----	2067
<i>P. penneri</i>	HugA	AF324468	1431	---GCA--T--A--G--T-----		--AT-A--T-A--GT--T--T-A-----	2023

selected from a positive ESBL-phenotypic screening during 2001 to spring 2007. All *K. oxytoca* isolates (n=34) revealed an ESBL-phenotype by screening with Etest using cefotaxime with and without clavulanic acid. All isolates were negative in the corresponding test with ceftazidime. Similarly, a majority of *K. pneumoniae* isolates (16 of 20) revealed an ESBL-phenotype in both ESBL Etests. Two of the *K. pneumoniae* isolates revealed an ESBL-phenotype only with cefotaxime and two isolates only with ceftazidime, respectively.

***bla*CTX-M PCR amplification and partial DNA sequence analysis**

DNA sequencing of M13-sequence-tagged universal CTX-M PCR-amplicons of MDA-DNA derived from *K. pneumoniae* and *K. oxytoca* of clinical origin revealed the presence of *bla*CTX-M genes in 9 out of 20 *K. pneumoniae* and the presence of the K1-gene in all 34 *K. oxytoca* clinical isolates. According to the phylogenetic tree constructed from partial *bla*CTX-M, *bla*OXY and K1-DNA sequences located between the two universal degenerated primers (Fig.1), nine *K. pneumoniae* clinical isolates formed a unique cluster with *E. coli bla*CTX-M-15, [GenBank:AY044436] and *E. coli bla*CTX-M-28 [GenBank:AJ549244] which itself is closely related to the *C. freundii* CTX-M-3 [GenBank:Y10278], *K. oxytoca bla*CTX-M-3 [GenBank:AB185840], and *E. coli bla*CTX-M-1 [GenBank:X92506] cluster, respectively (Fig. 2). Similarly, the *K. oxytoca* K1 clinical isolates form a unique K1/*bla*OXY-2 cluster together with *K. oxytoca* K1 [GenBank:AF473577, AY077489, AY055205, AY077487, AY077485, and AY077488] and *K. oxytoca bla*OXY-2 [GenBank:Y17714], respectively (Fig 2). None of the *K. oxytoca* K1 clinical isolates clustered within the K1/*bla*OXY-1 cluster. Clearly, partial DNA sequence analysis of the CTX-M PCR-amplicons did not allow an unequivocal discrimination of the *bla*CTX-M genes. However, our data indicate the presence of a *bla*CTX-M-15/28 genotype in the *K. pneumoniae* clinical isolates.




Figure 2: Phylogenetic tree from partial Enterobacteriaceae *bla* CTX-M and K1-like DNA sequences. *K. pneumoniae* *bla* CTX-M-15/28 and *K. oxytoca* K1/OXY-2 form distinct cluster groups, distinguishable from the K1/OXY-1 cluster, respectively. *P. penneri* HugA, *P. vulgaris* CumA and K1, *C. sedlakii* and *C. amalonaticus* form separate clades.

Susceptibility testing of *K. oxytoca* with K1-genes and *K. pneumoniae* with ^{bla}CTX-M genes

The MIC-values for cefotaxime and ceftazidime for the *K. oxytoca* isolates were in the range of 0.5 to 8 mg/l and 0.125 to 4 mg/l, respectively. Corresponding MIC-values for the *K. pneumoniae* isolates with CTX-M genotypes were in the range of 64 to 256 mg/l and 16 to 256 mg/l, respectively. The susceptibility for piperacillin/tazobactam was lower in the *K. oxytoca* isolates with MIC-values ≥ 128 mg/l compared to MIC-values between 4 to 64 mg/l for the *K. pneumoniae* isolates.

***In silico* DNA sequence comparison**

The finding that the universal degenerated CTX-M primer-pair amplified the chromosomally located K1-enzyme in *K. oxytoca* prompted us to perform a DNA sequence alignment of the universal CTX-M primer-pair with *Enterobacteriaceae* ^{bla}CTX-M, ^{bla}OXY, K1, and K1-like genes retrieved from the Entrez Nucleotide database (Methods). As illustrated in figure 1, the universal degenerated CTX-M primers revealed a high degree of DNA sequence similarity between the target sequences present in the *E. coli*, *S. Typhimurium*, *C. freundii* and *C. amalonaticus* ^{bla}CTX-M type-gene; *K. oxytoca* ^{bla}CTX-M-3 and ^{bla}CTX-M-35 genes, *K. oxytoca* K1 and ^{bla}OXY-1 to ^{bla}OXY-6 genes; the chromosomally encoded *C. sedlakii* Sed-1 and *C. amalonaticus* CdiA showed a lower degree of sequence similarity compared to *C. koseri* CKO, *P. vulgaris* K1, *P. vulgaris* CumA, and *P. penneri* HugA genes, respectively. With the exception of *C. koseri* CKO, *P. vulgaris* K1, *P. vulgaris* CumA and *P. penneri* HugA DNA sequences, most of the nucleotide variations are observed at 5'-Y, R, K-3' positions in primer CTX-M-U1.SE and 5'-R, R, R, S, Y-3' positions (where R stands for purine, Y stands for pyrimidine, S stands for G or C, and K stands for G or T) in primer CTX-M-U2.AS (Fig. 1). The GC-rich 3'-ends of the primers are highly conserved within the

corresponding *bla*CTX-M, *bla*OXY, and K1 target DNA sequences. This may explain why the universal degenerated CTX-M primer-pair amplified *bla*CTX-M and K1 sequences.

Discussion

The increased prevalence of *Enterobacteriaceae* that produce *bla*CTX-M enzymes makes new demands on clinical routine microbiology laboratories to perform *bla*CTX-M typing. Due to the growing number of *bla*CTX-M enzymes, the traditional iso-electrofocusing appears not to be the method of choice for establishing an enterobacterial *bla*CTX-M genotype any longer. Molecular techniques for identification and classification of *bla*CTX-M genes in clinical isolates on a large scale have been described. Recently, a multiplex CTX-M PCR (MP-PCR) amplification assay was described which allows differentiation between different *bla*CTX-M subtype groups [21]. However, using this particular MP-PCR assay, we often observed non-specific PCR amplification in *K. oxytoca* isolates. Subsequent cloning and DNA sequencing analysis revealed that the unspecific PCR-amplicons represented K1-enzyme gene sequences. Thus, misinterpretation of strains as active *bla*CTX-M producers based on false positive PCR amplification might cause false reporting of *bla*CTX-M genes in *K. oxytoca*.

A different approach has been used by Galas and co-workers [22]. These authors described the use of a CTX-M-consensus primer-pair to establish a *bla*CTX-M-genotype in *Enterobacteriaceae*, including *K. oxytoca* [22]. However, *in silico* DNA sequence analysis reveals that this consensus CTX-M primer-pair [23] also targets *bla*OXY/K1-genes such as *K. oxytoca* *bla*OXY-2 [Genbank:Y17714] at positions 348-367 (MA1 primer) and 872-391 (MA2 primer), and K1 gene [GenBank:AY077482] at positions 369-378 (MA1 Primer) and 893-911 (MA2 primer), respectively. Thus, based on PCR amplification alone, it seems to be far from

clear whether these *K. oxytoca* isolates would have a ^{bla}CTX-M, or a ^{bla}OXY/K1-genotype, respectively. This question can only be settled by DNA-sequencing of the PCR amplicons.

The use of M13-sequence tagged PCR-amplicons in combination with M13-specific sequencing primers was originally described for sequencing of *Staphylococcus aureus* protein A (Spa-typing) PCR-amplicons [24]. Our results employing the same technique for sequencing of β -lactamase PCR amplicons convincingly demonstrate that the use of a M13-sequence tagged CTX-M.U1.SE primer allowed for an unequivocal discrimination of ^{bla}CTX-M and K1-genes. Moreover, our results support our previous findings indicating that ^{bla}CTX-M and K1-enzyme genes might have some degree of sequence similarity [13]. Extended *in silico* analysis furthermore revealed a high degree of sequence similarities between *Enterobacteriaceae* ^{bla}CTX-M, ^{bla}OXY 1-6, and K1 related sequences (Fig.1), respectively. Thus, based on PCR amplification alone using universal degenerated CTX-M primer-pairs, it would be difficult, not to say impossible to distinguish between an *Enterobacteriaceae* ^{bla}CTX-M or K1/OXY genotype if sequencing had not been performed.

Fournier and co-workers [8] have described the existence of two discrete groups of *K. oxytoca* ^{bla}OXY-1 and ^{bla}OXY-2 enzymes. Later on, it was shown that ^{bla}OXY-1 and ^{bla}OXY-2 genes are expressed in two genetic *K. oxytoca* groups, namely *K. oxytoca* strain SG266 and SG271, respectively [25]. So far, six groups of OXY β -lactamases have been identified and characterised in *K. oxytoca* [26]. In our study we have found that all *K. oxytoca* clinical isolates form a distinct *K. oxytoca* K1/OXY-2 cluster group distinguishable from the K1/OXY-1 and the *K. pneumoniae* CTX-M15/28 cluster group, respectively. Moreover, the phylogenetic tree that was established implies the existence of a chromosomally located β -lactamase super-gene family in *Enterobacteriaceae* (Fig.2). This is in agreement with

previous reports describing that chromosomally encoded class A β -lactamases found in *Klebsiella* species are highly conserved at the amino-acid level compared to class A β -lactamases found in other *Enterobacteriaceae* [27-31]. The *Citrobacter* spp. DNA sequences included in the phylogenetic tree form separate clades. This is in agreement with earlier reports showing that *C. koseri* CKO-1 and *C. amalonaticus* CdiA isolates carry highly divergent β -lactamase genes despite the fact that they show a highly similar biochemical profile and 16S rDNA sequence similarity [32]. Biochemical methods may not always be adequate to identify *Klebsiella* spp. and their phylogenetic groups in clinical microbiology laboratories because several species share similar biochemical profiles [33,34]. Therefore, molecular techniques as applied in the present study may help to accomplish bacterial genotyping at reasonable costs and time.

MIC-value determination of piperacillin/tazobactam in this study also distinguished between *K. oxytoca* with K1 β -lactamase from CTX-M producing *K. pneumoniae*, showing higher MIC-values. Furthermore, the MIC-values for cefotaxime and ceftazidime for *K. oxytoca* with K1-genes was lower than for CTX-M producing *K. pneumoniae*. Similar results have been reported by Potz and co-workers [35].

Conclusion

The PCR-based molecular typing method described here enables a rapid and reliable identification of CTX-M and OXY/K1-genes. The principles used in the present study can be applied to any situation in where antimicrobial resistance genes are to be sequenced. This is desirable because only sequencing of full-length reading frames will allow for an unequivocal discrimination between various subtypes of antimicrobial resistance genes such as *bla*CTX-M, *bla*SHV and *bla*TEM gene-families, respectively. Moreover, the use of M13-sequence tagged

primers in PCR amplification assays facilitates amplicon sequencing since only one single sequencing primer (M13) is required.

Competing interests

The authors declare that they have no competing interests

Authors' contributions

HJM, MT and LEN participated in the conception, design, drafting of the manuscript, and final approval of the version to be published. HJM and MT were responsible for the acquisition, analysis and interpretation of the molecular biology based data. MT and LEN were responsible for the clinical strain collection and phenotypic screening, analysis and interpretation of phenotypic data.

Acknowledgments

This study was financially supported in part by a County Medical Centre Östergötland (LMC) Grant (21403-ESBL) the Research Council in the South East of Sweden (FORSS-3971), and the Molecular Biology Program, Clinical Microbiology-LMC, Linköping, Sweden. We greatly acknowledge the technical assistance of M. V. Nilsson during the initial phase of this study and the critical reading and commenting on the manuscript by Dr. Jon Jonasson.

References

1. Tzouveleki LS, Tzelepi E, Tassios PT, Legakis NJ: **CTX-M-type β -lactamases: An emerging group of extended-spectrum enzymes.** *Int J Antimicrob Agents* 2000, **14**:137-142.
2. Bonnet R: **Growing group of extended-spectrum β -lactamases: the CTX-M enzymes.** *Antimicrob Agents Chemother* 2004, **48**:1-14.
3. **Amino Acid Sequences for TEM, SHV and OXA Extended-Spectrum and Inhibitor Resistant β -Lactamases** [<http://www.lahey.org/studies>]
4. Rossolini GM, Andrea MMD, Mugnaioli C: **The spread of CTX-M-type extended-spectrum β -lactamase.** *Clin Microbiol Infect Dis* 2008, **14**:33-41.
5. Arakawa Y, Ohta M, Kido N, Mori M, Ito H, Komatsu T, Fujii Y, Kato N: **Chromosomal β -lactamase of *Klebsiella oxytoca*, a new class A enzyme that hydrolyzes broad-spectrum β -lactam antibiotics.** *Antimicrob Agents Chemother* 1989, **33**:63-70.
6. Fournier B, Arlet G, Lagrange PH, Philippon: ***Klebsiella oxytoca*: Resistance to aztreonam by overproduction of the chromosomally encoded β -lactamase.** *FEMS Microbiol Lett* 1994, **11**: 31-36.
7. Emanuel EL, Gagnon J, Waley G: **Structural and kinetic studies on β -lactamase K1 from *Klebsiella aerogenes*.** *Biochem J* 1986, **234**:343-347.
8. Livermore DM, Yuan M: **Antibiotic resistance and production of extended-spectrum β -lactamases amongst *Klebsiella* spp. from intensive care units in Europe.** *J Antimicrob Chemother* 1996, **38**:409-424.
9. Fournier B, Roy PH, Lagrange PH, Philippon A: **Chromosomal β -lactamase of *Klebsiella oxytoca* are divided into two main groups, bla^{OXY-1} and bla^{OXY-2} .** *Antimicrob Agents Chemother* 1996, **40**:454-459

10. Pitout JDD, Hossain A, Hanson ND: **Phenotypic and molecular detection of CTX-M- β -lactamases produced by *Escherichia coli* and *Klebsiella* spp.** *J Clin Microbiol* 2004, **42**:5715-5721.
11. Soge O, Queenan, Ojo KK, Adeniyi BA, Roberts MC: **CTX-M-15 extended-spectrum β -lactamase from Nigerian *Klebsiella pneumoniae*.** *J Antimicrob Chemother* 2006, **57**:24-30.
12. Boyd D, Tyler AS, Christianson S, McGeer A, Muller MP, Willey BM, Bryce E, Gardam M, Nordmann P, Mulvey MR, and the Canadian nosocomial infection surveillance program, Health Care: **Complete nucleotide sequence of a 92-Kilobase plasmid harbouring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada.** *Antimicrob Agents Chemother* 2004, **48**:3758-64.
13. Monstein, H-J, Östholm-Balkhed Å, Nilsson MV, Nilsson M, Dornbusch K, Nilsson LE: **Multiplex PCR amplification assay for the detection of *bla*^{SHV}, *bla*^{TEM} and *bla*^{CTX-M} genes in *Enterobacteriaceae*.** *APMIS* 2007, **115**:1400-1408.
14. **The Swedish Reference Group for Antibiotics** [<http://www.srga.org>]
15. **The American Type Culture Collection** [<http://www.lgcstandards-atcc.org>]
16. **The Culture Collection, University of Gothenburg** [<http://www.ccug.se>]
17. Monstein H-J, Olsson C, Nilsson I, Grahn N, Benoni C, Ahrné S: **Multiple displacement amplification of DNA from human colon and rectum biopsies. Bacterial profiling and identification of *Helicobacter pylori*-DNA by means of 16s rDNA-based TTGE and pyrosequencing analysis.** *J Microbiol Meth* 2005, **63**:239-247.
18. **CLC bio** [<http://www.clcbio.com>]
19. **NCBI Entrez Nucleotide** [<http://www.ncbi.nlm.nih.gov/nucleotide>]
20. **EMBL-EBI ClustalW2** [<http://www.ebi.ac.uk/Tools/clustalw2>]

21. Woodford N, Fagan EJ, Ellington MJ: **Multiplex PCR for the rapid detection of genes encoding CTX-M extended-spectrum β -lactamases.** *J Antimicrob Chemother* 2006, **57**:154-155.
22. Galas M, Decousser J-W, Breton N, Godard T, Allouch PY, Pina P, and the College de Bacteriologie virology Hygiène (ColBVH) study group: **Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum β -lactamase-producing *Enterobacteriaceae* in France.** *Antimicrob Agents Chemother* 2008, **52**:786-789.
23. Saladin M, Cao VTB, Lambert T, Donay J-L, Herrmann J-L, Ould-Hocine Z, Verdet C, Delisle F, Philippon A, Arlet G: **Diversity of CTX-M β -lactamases and their promoter regions from *Enterobacteriaceae* isolated in three Parisian hospitals.** *FEMS Microbiol Lett* 2002, **209**:161-168.
24. Frénay HM EM, Bunschoten AE, Schouls LM, van Leeuwen WJ, Vandenbroucke-Grauls CMJE, Verhof J, Mooi RF: **Molecular typing of Methicillin-resistant *Staphylococcus aureus* on the basis of Protein A gene polymorphism.** *Eur J Clinical Microbiol Infect Dis* 1996, **15**:60-64.
25. Granier SA, Leflon-Guibout V, Goldstein FW, Nicolas-Chanoine M-H: **New *Klebsiella oxytoca* β -lactamase genes *bla*^{OXY-3} and *bla*^{OXY-4} and a third group of *K. oxytoca* based on *bla*^{OXY-3}.** *Antimicrob Agents Chemother* 2003, **47**:2922-2928.
26. Fevre C, Jbel M, Passet V, Weill FX, Grimont PAD, Brisse S: **Six groups of OXY β -lactamase evolved over millions of years in *Klebsiella oxytoca*.** *Antimicrob Agents Chemother* 2005, **49**:3453-3462.
27. Perilli M, Franceschini N, Segatore B, Amicosante G, Orator A, Duez C, Joris B, Frère JM: **Cloning and nucleotide sequencing of the gene encoding the β -lactamase from *Citrobacter diversus*.** *FEMS Microbiol Lett* 1991, **67**:79-84.

28. Péduzzi J, Farzaneh S, Reynaud A, Barthélémy M, Labia R: **Characterization and amino acid sequence analysis of a new oxymino cephalosporin-hydrolyzing class A β -lactamase from *Serratia fonticola*.** *Biochim Biophys Acta* 1997, **1341**:58-70.
29. Nukaga M, Mayama K, Crichlow GV, Knox JR: **Structure of the extended-spectrum class A β -lactamase from *Proteus vulgaris* K1.** *J Mol Biol* 2002, **317**:109-117.
30. Petrella S, Clermont D, Casin I, Jarlier V, Sougakoff W: **Novel class A β -lactamase Sed-1 from *Citrobacter sedlakii*: Genetic diversity of β -lactamases within the *Citrobacter* genus.** *Antimicrob Agents Chemother* 2001, **45**:2287-2298.
31. Petrella S, Renard M, Ziental-Gelus N, Clermont D, Jarlier V, Sougakoff W: **Characterization of the chromosomal class A β -lactamase CKO from *Citrobacter koseri*.** *FEMS Microbiol Lett* 2006, **254**:285-292.
32. Underwood S, Avison MB: ***Citrobacter koseri* and *Citrobacter amalonaticus* isolates carry highly divergent β -lactamase genes despite the having high levels of biochemical similarity and 16S rRNA sequence homology.** *J Antimicrob Chemother* 2004, **53**:1076-1080.
33. Hansen DS, Aucken HM, Abiola T, Podschun R: **Recommended test panel for differentiation of *Klebsiella* species on the basis of a trilateral interlaboratory evaluation of 18 biochemical tests.** *J Clin Microbiol* 2004, **42**:3665-3669.
34. Alves MS, Dias de Castro AC, Riley LW, Moreira BM: **Identification of clinical isolates of Indole-positive and Indole-negative *Klebsiella* spp.** *J Clin Microbiol* 2006, **44**:3640-3646.
35. Potz NA, Colman M, Warner M, Reynolds R, Livermore DM: **False-positive extended-spectrum beta-lactamase tests for *Klebsiella oxytoca* hyperproducing K1 beta-lactamase.** *J Antimicrob Chemother* 2004, **53**:545-547.